MK-801 induced Schizophrenia Model Development Service

Are you currently facing long drug development cycles and challenges in creating translatable animal models for complex central nervous system (CNS) disorders? Our MK-801-induced schizophrenia model development services help you accelerate drug discovery and obtain high-quality preclinical data through advanced in vivo pharmacology and translational biomarker assays.

The glutamate hypofunction theory of schizophrenia is a central pillar of modern neuropharmacology. This hypothesis suggests that a deficit in NMDA receptor function is a key driver of the disorder's debilitating symptoms. As a potent, non-competitive NMDA receptor antagonist, MK-801 is a well-established pharmacological tool to induce a phenotype in rodents that robustly mimics aspects of human schizophrenia, making it an invaluable tool for preclinical drug discovery.

How Our MK-801-Induced Schizophrenia Model Development Services Can Assist Your Project

At Creative Biolabs, we provide comprehensive solutions for evaluating novel therapeutic compounds against a range of schizophrenia-like symptoms. Our services are meticulously designed to generate reliable and reproducible data that validates your compound's efficacy, informs lead optimization, and de-risks your program ahead of clinical trials. We offer a holistic assessment of your compound's effect on positive, negative, and cognitive symptoms, providing you with a complete and compelling data package.

Discover How We Can Help - Request a Consultation

Workflow

The typical timeframe for our services ranges from 6 to 12 weeks, depending on the complexity of the study design and the number of compounds to be tested. This is a general guide; factors such as compound solubility, required administration routes, and specific endpoints can influence the duration.

Why Choose Us?

Choosing CBL means partnering with a team that has a deep, nuanced understanding of neuropharmacology and a commitment to generating high-quality, actionable data. Our expertise and specialized platform provide a distinct advantage in the competitive landscape of CNS drug discovery.

Experience the Advantage - Get a Quote Today

Client Successes

• [Exceptional Reliability] "Using CBL's schizophrenia models has significantly improved the reliability and translatability of our preclinical data. The detailed reports and expert support were invaluable in moving our lead compound forward." - (2024), Je Gz
• [Accelerated Screening] "CBL's fast-track induced models allowed us to screen our candidate library in a fraction of the time we had anticipated. This efficiency is critical for our small biotech." - (2023), Sh Kr
• [In-Depth Insights] "The addition of biomarker analysis on brain tissue provided an extra layer of confidence in our compound's mechanism of action. The data was clear, and the insights from the CBL team were exceptional." - (2023), Ax Po

MK-801-Induced Schizophrenia Model

The MK-801 model provides a powerful platform for studying both the positive and negative symptoms of schizophrenia. Its ability to induce a state of "hypofrontality," or reduced prefrontal cortex activity, which is a hallmark of the human condition, offers a uniquely translational endpoint for drug evaluation. In addition, the model can be used to assess its effect on Prepulse Inhibition (PPI), a key measure of sensory gating that is impaired in schizophrenic patients.

Fig.1 Performance of the rats in condition 1 (motor response switch).¹

What We Can Offer

Our expertise in MK-801-induced schizophrenia model development services allows us to offer a flexible and comprehensive platform designed to meet the unique needs of your research program.

• Customized Study Design: We provide fully customizable study protocols, allowing for the optimization of disease induction, dosing regimens, and behavioral or biochemical endpoints tailored to your compound's specific mechanism of action.
• Comprehensive Model Suite: We offer a wide range of models, including acute and chronic MK-801 models, as well as AMPH and PCP-induced models, enabling you to study both positive, negative, and cognitive symptoms.
• Advanced Translational Biomarkers: Our services go beyond standard behavioral assays to include cutting-edge translational endpoints like in vivo electrophysiology for assessing Auditory Steady-State Response (ASSR) and ex vivo analysis for oxidative stress markers.
• Consistent and Reliable Data: We guarantee the stability of our models and the reproducibility of our data through rigorous quality control procedures and standardized protocols, ensuring your results are reliable and defensible for regulatory submissions.
• Streamlined Project Management: We provide efficient project management from initial consultation to final report delivery, including clear communication and detailed documentation at every stage of the process.

Related Services

In addition to our core services, we offer a range of complementary services that may be relevant to your project, including:

• Target Identification & Validation
• Compound Screening & Profiling
• Pharmacokinetic/Pharmacodynamic (PK/PD) Studies
• Neuroinflammation Research Models

FAQs

For more information and to discuss your project in detail, please do not hesitate to reach out to our team.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Svoboda, Jan et al. "Acute administration of MK-801 in an animal model of psychosis in rats interferes with cognitively demanding forms of behavioral flexibility on a rotating arena." Frontiers in behavioral neuroscience vol. 9 75. 1 Apr. 2015, doi:10.3389/fnbeh.2015.00075. Distributed under Open Access license CC BY 4.0, without modification.